No matches

14 search results for: CRSwNP

IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in <b>CRSwNP</b>
On Demand
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.

View more
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: ​ Going Beyond Symptom Control​
Congress
31
May
2024
Congress
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: ​ Going Beyond Symptom Control​

Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.

View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: LebanonChange country/region